[
  {
    "ts": "2025-12-18T09:45:00+00:00",
    "headline": "Takeda says $4B TYK2 drug succeeds in large psoriasis studies",
    "summary": "The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.",
    "url": "https://www.biopharmadive.com/news/takeda-zasocitinib-tyk2-psoriasis-drug-results-nimbus/808237/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "76a69559-4d03-39fd-a082-f65e0ab430ff",
      "content": {
        "id": "76a69559-4d03-39fd-a082-f65e0ab430ff",
        "contentType": "STORY",
        "title": "Takeda says $4B TYK2 drug succeeds in large psoriasis studies",
        "description": "",
        "summary": "The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.",
        "pubDate": "2025-12-18T09:45:00Z",
        "displayTime": "2025-12-18T09:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "BioPharma Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3g5.ulK0vcCqcdyFlYvVw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DH6ljKWVk5FO27mUzvHUcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/takeda-zasocitinib-tyk2-psoriasis-drug-results-nimbus/808237/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/takeda-says-4b-tyk2-drug-094500434.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TAK"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]